The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …

Aims The effects of adding a sodium–glucose cotransporter 2 (SGLT2) inhibitor to a
mineralocorticoid receptor antagonist (MRA) or an angiotensin receptor–neprilysin inhibitor …

The coronary microcirculation plays a cardinal role in regulating coronary blood flow to meet
the changing metabolic demands of the myocardium. Coronary microvascular dysfunction …

Background There are few contemporary data on outcomes, costs, and treatment following a
hospitalization for heart failure (hHF) in epidemiologically representative cohorts. Objectives …

Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly
reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse …

Background Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse
outcomes compared with sinus rhythm, and may modify the effects of therapy. Objectives …

The specific mechanism of sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure
(HF) needs to be elucidated. In this study, we use SGLT2-global-knockout (KO) mice to …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to treat
diabetes mellitus. Abundant evidence has shown that SGLT2 inhibitors can reduce …

Heart failure (HF) represents a major public health concern with increasing prevalence
among aging populations, with multifactorial pathophysiology including inflammation …

Chronic heart failure is one of the most common causes of hospitalization and death in
industrialized countries. Demographic changes with an aging population are expected to …